

# Detection of the Frequency of the Novel TT virus by PCR and Its Role in the Induction of Hepatic Injuries in Blood Donors in West Azerbaijan, Iran

Ahad Mokhtarzadeh <sup>1</sup>, Majid Bouzari <sup>2</sup>

1. Microbiology section, Department of Biology, University of Rabe Rashidi, Tabriz.

2. Microbiology section, Department of Biology, University of Isfahan, Isfahan.

Corresponding author: Ahad Mokhtarzadeh, Microbiology section, Department of Biology, University of Rabe Rashidi, Tabriz. (Phone:+98 411-3334120, Fax:+98 411-3334076, E-mail: ahad.mokhtarzadeh@gmail.com)

## Abstract

**Background:** In 1997, a novel DNA virus was isolated from the serum of a patient in Japan, and it was named TT virus (TTV). As the virus is replicated in liver and has the ability to induce apoptosis in hepatocytes (Hepatocellular carcinoma cells) it is hypothesized that TTV is an opportunistic virus and in certain conditions causes liver damage. In this study the frequency of infection with TTV was detected in two groups of healthy and hepatitis B infected blood donors in the West Azerbaijan Province.

**Material and Methods:** Serum samples were collected from 100 healthy and 40 HBs Ag positive donors in west Azerbaijan Blood Transfusion Center. Patients' characteristics, sex, age and blood groups were recorded. The levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in the sera were measured and then DNA was extracted and polymerase chain reaction (PCR) was performed using T801 and T935 consensus primers to amplify a 199 bp segment of a much conserved non-coding region of the genome (UTR).

**Results:** TTV was detected in 69% and 75% of healthy and hepatitis B infected blood donors respectively. No significant difference was observed in the frequency of the infection with TTV in different blood groups or age groups ( $P>0.05$ ). In each group of blood donors the level of ALT and AST were not significantly different in TTV infected and non-infected individuals ( $P>0.05$ ).

**Conclusion:** Regarding the high frequency of infection in healthy individuals and considering the level of hepatic enzymes in TTV infected individuals; it seems that the virus or at least its investigated genotypes have not been pathogenic for the infected individuals examined.


**Keywords:** TT virus, Blood donors, HBV, ALT, AST, PCR.

## Introduction

In 1997, a novel human DNA virus, unrelated to the known hepatitis viruses, was isolated from the serum of a patient with post-transfusion hepatitis of unknown etiology in Japan.<sup>1</sup> Representational difference analysis (RDA) was performed for the specific amplification of nucleic acid sequences present in the serum of the patient during the period of his acute hepatitis.<sup>1, 2</sup> It was named Torque Teno virus (TTV). TTV is an unenveloped, single-stranded circular DNA virus containing a genome of 3900 nucleotides in the full length sequence.<sup>3, 4</sup>

TT viruses (TTV) are ubiquitous in nature and have been demonstrated in more than 90% of serum samples from healthy individuals where they persist over time.<sup>4</sup> Viral particles have been purified from feces<sup>5</sup> and are also excreted in saliva, breast milk and bile.<sup>6,7,8</sup> Furthermore, vertical and sexual transmissions have been reported.<sup>9</sup>

The cause of liver disease is still unknown in 50% of patients with fulminant hepatitis, 10%–20% of patients with acute hepatitis and 5%–10% of patients with chronic liver disease, including chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. The cases cannot be ascribed to A to E



**Figure 1.** The Products of PCR in 1.5% agarose gel electrophoresis stained with ethidium bromide. M, 100 bp ladder; P, positive control; 1, 2,3,4,5 positive samples and N, negative sample.

**Table1.** Frequency of TT Virus in West Azerbaijan blood donors

Sample*	TTV Positive N (%)	TTV Negative N (%)
Healthy	69 (69)	31 (31)
HBs-Ag Positive	30 (75)	10 (25)
Total	99 (71)	41 (29)

\* P>0.05

**Table 2.** Distribution of TT virus in healthy blood donors in different blood and age groups

Infection status	Age groups, years*			Blood groups*			
	18-30	31-43	44-56	A	B	AB	O
TTV+, Number	30	28	11	29	18	9	13
TTV-, Number	17	11	3	14	8	3	6
Total, Number	47	39	14	43	26	12	19
TTV+, Percent	63	71	78	67	69	75	68

\* P > 0.05

hepatitis viruses and GB virus C (also known as hepatitis G virus) or to certain enteroviruses, adenoviruses, parvovirus B19 and etc, which are suspected of occasionally causing liver damage.<sup>1,10</sup> Due to the history of TTV as a potential hepatitis virus, liver as a main target organ for TTV infection has also been studied extensively. TTV is found by *in situ* methods in the nucleus and/or the cytoplasm of hepatocytes in patients with liver damage<sup>11, 12</sup> without any cytopathological changes.<sup>13, 14</sup> Both acute resolving and chronic persistent hepatitis

infection have been identified among TTV-infected individuals.<sup>15</sup> Furthermore, TTV has been detected in a variety of liver diseases including non A-G post-transfusion hepatitis, fulminant hepatic failure, chronic persistent hepatitis, cryptogenic liver disease and hepatocellular carcinoma.<sup>4, 16, 17, 18</sup> Evidence of potential hepatotropism of TTV was reported with TTV DNA titres shown to be 10-100 folds greater in liver tissue than in serum.<sup>19</sup> Although the virus was originally introduced as a novel hepatitis virus, the evidence has not been

available for its causative role in any of the significant pathological entities.<sup>20</sup>

As TTV is transmitted by blood transfusion and due to the potential pathogenic effects predicted for some genotypes of the virus and also lack of information about the frequency of the virus in West Azerbaijan, the aim of this study was to detect the frequency of infection with TTV in two groups of healthy and hepatitis B infected blood donors in the area by amplification of a conserved region of the viral genome and the possible effects of co-infection in individuals infected with hepatitis B virus.

## Materials and Methods

### Serum samples

In this study two groups of healthy and hepatitis B positive blood donors of Urmia Blood Transfusion Center were tested. Serum samples were collected from 100 healthy donors (HBs Ag negative, Anti-HCV antibody negative, Anti-HIV antibody negative and negative for Syphilis) and 40 HBs Ag positive donors from June 2006 to May 2007. Patients' characteristics, sex, age and blood groups were recorded. Licenses from the Urmia Blood Transfusion Organization to receive blood samples and consent of the donors for the necessary tests were obtained. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were determined in all the samples with Man Transaminase Kit (Man, Iran). DNA was extracted and TTV DNA was detected by polymerase chain reaction (PCR) using T935 and T801 primers.

### DNA extraction

Viral DNA was extracted using phenol/chloroform after treatment of 200 µL of serum with 0.5 mL of proteinase K in the presence of 0.2 M NaCl, 0.25 % Sodium Dodecyl Sulfate (SDS), for 2 h at 65°C. The pellet was dried and resuspended in distilled water or TE (Tris-HCL buffer (10 mM, pH 8.0) containing 1 mM EDTA) solution after precipitation with ethanol.

### Detection of TT Virus DNA by PCR

The T801 and T935 primers were used for amplification of a highly conserved noncoding region (UTR) of the viral genome.<sup>21, 22</sup> The sequences of TT virus specific primers were: T801: 5' - GCT ACG TCA CTA ACC ACG TG - 3' (sense, 6 - 25 nt) and T935: 5' - CTG CGG TGT GTA AAC TCA CC - 3' (antisense, 185 - 204 nt).

DNA was amplified by a single round of PCR performed with 3 µL of DNA in a 25 µL reaction mixture containing 1 U of Smar Taq DNA Polymerase (Cinnagen, Iran), 0.4 µM of each primers, 240 µM of each dNTPs, 20 mM of Tris - HCL, 3 mM MgCl<sub>2</sub>, 50 mM KCL and 20 mM ammonium sulfate. Thermal cyclor conditions were as follows: denaturation at 94°C for 5 min followed by 40 cycles at 94°C denaturation for 20 sec, annealing at 57°C for 25 sec and extension at 72°C for 5 min. PCR products (10 µL) were loaded on 2% agarose gel (Sigma, Germany) containing ethidium bromide and electrophoresed.

A positive control which was already sequenced with accession number of DQ 133465 in Gene Bank was used.<sup>23</sup>

### Statistical analysis

One-way ANOVA, Tukey-Kramer, Kruskal- Wallis, Dunn's and Fisher's Exact tests were used for statistical analyses using GraphPad InStat Software version 3.05 (GrapPad, USA). P value <0.05 was considered statistically significant.

## Results

In PCR 199 bp product was detected in 99 out of 140 (72%) blood donors in whom 69% and 75% were detected in healthy and hepatitis B infected blood donors respectively (Figure 1 and Table 1). No significant differences were observed in the frequency of the infection with TTV in different blood and age groups (P>0.05) (Tables 2 and 3). In each group of blood donors the level of ALT and AST were not significantly different in TTV infected and non-infected individuals (P>0.05) (Tables 4 and 5). Significant differences were observed in the level of hepatic enzymes among the healthy and HBV infected groups (P<0.05). As the number of female blood donors was only a few, we did not compare their results with males due to the lack of statistical power.

## Discussion

TTV is a widespread virus, having been found in a large proportion of general population. The high prevalence of TTV in healthy blood donors in different countries poses a quandary for the transfusion services. Its incidence varies in different countries.<sup>4</sup>

**Table 3.** Distribution of TTV virus in HBV positive donors in different blood and age groups

Infection status	Age groups*, years			Blood groups*			
	18-30	31-43	44-56	A	B	AB	O
TTV+, Number	14	11	5	9	10	5	6
TTV-, Number	6	2	2	4	3	1	2
Total, Number	20	13	7	13	13	6	8
TTV+, Percent	70	84	71	69	77	83	75

\* P &gt; 0.05

**Table 4.** Comparison of ALT serum levels (IU/L) in healthy and HBV infected donors

Comparison groups	Mean±SD	P-Value	
Healthy TTV+ versus Healthy TTV-	16.52±10.62	17.25±9.08	N.S
Healthy TTV+ versus HBV+ TTV+	16.52±10.62	37.95±25.49	P<0.001
Healthy TTV+ versus HBV+ TTV-	16.52±10.62	36.31±20.72	P<0.01
Healthy TTV- versus HBV+ TTV+	17.25±9.08	37.95±25.49	P<0.001
Healthy TTV- versus HBV+ TTV-	17.25±9.08	36.31±20.72	P<0.01
HBV+ TTV+ versus HBV+ TTV-	37.95±25.49	36.31±20.72	N.S

N.S, not statistically significant; SD, standard deviation

**Table 5.** Comparison of AST serum levels (IU/L) in healthy and HBV infected donors

Comparison groups	Mean±SD	P-Value	
Healthy TTV+ versus Healthy TTV-	18.71±9.84	20.68±10.64	N.S
Healthy TTV+ versus HBV+ TTV+	18.71±9.84	41.09±22.21	P<0.001
Healthy TTV+ versus HBV+ TTV-	18.71±9.84	43.38±22.76	P<0.001
Healthy TTV- versus HBV+ TTV+	20.68±10.64	41.09±22.21	P<0.001
Healthy TTV- versus HBV+ TTV-	20.68±10.64	43.38±22.76	P<0.001
HBV+ TTV+ versus HBV+ TTV-	41.09±22.21	43.38±22.76	N.S

N.S, not statistically significant; SD, standard deviation

When the original TTV isolate was discovered, TTV (genotype 1) detectable by N22 PCR was found in three of five patients with post-transfusion acute hepatitis of unknown etiology and the presence of TTV genotype 1 was closely associated with the serum ALT level.<sup>1</sup> Infection with TTV is characterized by persistent lifelong viremia in human beings, with circulating levels of up to 10<sup>6</sup> copies/ml in general population.<sup>24</sup> Furthermore TTV double-stranded replicative intermediates are detected in the liver, as documented by in situ hybridization and/or quantitative PCR.<sup>10,14</sup>

However further researches have revealed contradictory results showing that TTV is not

associated with ALT levels or with any form of hepatitis (post-transfusion, chronic idiopathic, acute or fulminant).<sup>25, 26, 27</sup> At present, despite evidence for hepatic replication of TTV, TTV does not fulfill the criteria for being a hepatitis virus. For TTV to be characterized as a hepatitis virus, direct causal evidence of cytopathology or specific inflammatory changes associated with replication as well as statistical difference in comparison with controls in terms of TTV prevalence, loads, sequence variation, genotype distribution or co-infection among liver disease patients have to be demonstrated in future studies.

Due to the great genetic variability of TTV, the choice of the viral DNA segment targeted for amplification has an enormous impact on PCR assay sensitivity, possibly more so than for most viruses. For historical reasons, the N22 region of ORF1 has been extensively targeted in nested or heminested PCR protocols. The primers designed on this region have been considerably improved over time, but nonetheless, they still may fail to amplify TTV isolates other than types 1 to 6, especially if the virus content in test samples is low. This limit has been solved only partly by using multiple sets of primers. Due to its higher conservation, the UTR of the TTV genome is much more suitable for primer design.<sup>4</sup> Indeed, generally UTR PCR has proven satisfactory at detecting most if not all the 16 TTV genotypes currently recognized and compared to ORF1 PCR, has greatly increased the rates of plasma or serum samples that give a positive reaction to TTV DNA: from 23 to 92% in the study by Takahashi et al.<sup>21</sup>, from 9 to 50% in the study by Irving et al.<sup>28</sup> and from 20 to 95% in the study by Itoh et al.<sup>22</sup>

The results of this study also revealed a high prevalence of the virus in the population of the West Azerbaijan province. The results obtained in West Azerbaijan by using T801 and T935 consensus primers that are able to identify all the genotypes of this virus, like other parts of the world, is high.<sup>4</sup> The prevalences of 85, 93, 96, 82, 100, 98, 73, 57 and 82 percent were reported in Egypt, Japan, Myanmar, Nepal, Saudi Arabia, Singapore, Finland, Britain and Bolivia respectively.<sup>4</sup> In Isfahan and East Azerbaijan the prevalences were 79.5 and 65 percent respectively.<sup>23, 29</sup>

Meanwhile, the prevalences reported using primers designed for N22 regions of the virus in Egypt, Japan, Saudi Arabia, Finland, UK, USA and Bolivia were 29, 58, 19, 17, 10, 11 and 20 percent respectively.<sup>4</sup> Such prevalences were 41%<sup>30</sup>, 4.4% and 11%<sup>31</sup> and 22.4%<sup>32</sup> in Tehran and 23.7% in Ahvaz<sup>33</sup>.

This shows that primers designed for coding regions (N22) of the virus are more specific (detect a limited number of specific genotypes) and does not show the actual prevalence of the virus.<sup>4,30,31,32,33</sup> So, the high frequency of the virus in this study compared to the lower frequencies reported in other studies in Iran could be correlated to the methodology and the PCR primers used.

In the present study, TTV infection was detected in 69% and 75% of the healthy and hepatitis B infected blood donors respectively. No significant difference was observed in the frequency of the infection with TTV in different blood and age groups ( $P>0.05$ ). In each group of blood donors the levels of ALT and AST were not significantly different in TTV infected and non-infected individuals ( $P>0.05$ ). This fact indicates that TTV does not have any role in increasing of the levels of the hepatic enzymes. Significant differences were observed in the levels of hepatic enzymes between the healthy and HBV infected groups ( $P<0.05$ ). This could be correlated with the effect of HBV rather than TTV. In conclusion, regarding the high frequency of infection in healthy individuals and considering the level of hepatic enzymes in TTV infected individuals; it seems that the virus or at least its investigated genotypes have not been pathogenic in the infected individuals examined. Although the precise relationship between TTV infection and viral hepatitis remains to be established, recent studies indicate that further clinical studies of TTV infected patients, in relation to TTV genotype, viral load, and quasispecies complexity are warranted.

## Conclusion

As the blood donors tested positive for HBs Ag had no acute or chronic clinical signs, they may have been in early stages of the infection, so detecting the frequency of infection in patients with acute and chronic hepatitis with clinical signs is suggested. As certain genotypes may be pathogenic, determining the genotypes of the virus is also suggested.

## Acknowledgements

This research was supported by grants provided by the Postgraduate Office of the University of Isfahan. We would like to thank Urmia Blood Transfusion Organization Center, Dr. Amir Ollae, Mr. Abolgasem Mehmannaavaz and Mr. Shamsedini for blood sample preparation.

## References

1. Nishizawa T, Okamoto H, Konishi K, Yoshizawa H, Miyakawa Y, Mayumi M. A novel DNA virus (TTV) associated with elevated transaminase levels in

posttransfusion hepatitis of unknown etiology. *Biochem Biophys Res Commun.* 1997; 241:92–7.

2. Lisitsyn N, Wigler M. Cloning the differences between two complex genomes. *Science.* 1993; 259: 946–51.

3. Mushahwar LR, Erker JC, Muerhoff AS, Leary TP, Simons JN, Birkenmeyer LG, et al. Molecular and biophysical characterization of TT virus: evidence for a new virus family infecting human. *Proc Natl Acad Sci U S A.* 1999; 96: 3177–82.

4. Bendinelli M, Pistello M, Maggi F, Fornai C, Freer G, Vatteroni ML. Molecular properties, biology, and clinical implications of TT virus, a recently identified widespread infectious agent of humans. *Clin Microbiol Rev.* 2001; 14: 98-113.

5. Okamoto H., Akahane Y, Ukita M, Fukuda M, Tsuda F, Miyakawa Y, et al. Fecal excretion of a nonenveloped DNA virus (TTV) associated with posttransfusion non-A-G-hepatitis. *J Med Virol.* 1998; 56: 128–32.

6. Itoh Y, Takahashi M, Fukuda M, Shibayama T, Ishikawa T, Tsuda F, et al. Visualization of TT virus particles recovered from the sera and feces of infected humans. *Biochem Biophys Res Commun.* 2000; 279: 718–24.

7. Hayakawa E, Edamoto Y, Xin D, Tran HT, Iwaki Y, Sato Y, et al. Detection of TT virus in human bile juice. *Jpn J Infect Dis.* 2001; 54: 127–8.

8. Schroter M, Polywka S, Zollner B, Schafer P, Laufs R, Feucht HH. Detection of TT virus DNA and GB virus type C/hepatitis G virusRNA in serum and breast milk: determination of mother-to-child transmission. *J Clin Microbiol.* 2000; 38: 745–7.

9. Ross RS, Viazov S, Runde V, Schaefer UW, Roggendorf M. Detection of TT virus in specimens other than blood. *J Clin Virol.* 1999; 13:181–184.

10. Okamoto H, Mayumi M. TT virus: virological and genomic characteristics and disease associations. *J Gastroenterol.* 2001; 36: 519–29.

11. Cheng J, Hada T, Liu W, Imanishi H, Iijima H, Shimomura S, et al. Investigation of TTV by in situ hybridization in patients with chronic hepatitis. *Hepatol Res.* 2000; 18: 43–53.

12. Comar M, Ansaldi F, Morandi L, Dal Molin G, Foschini PM, Croce SL, et al. In situ polymerase chain reaction detection of transfusion transmitted virus in liver biopsy. *J Viral Hepat.* 2002; 9:123–7.

13. Ohbayashi H, Tanaka Y, Ohoka S, Chinzei R, Kakinuma S, Goto M, et al. TT virus is shown in the liver by in situ hybridization with a PCR-generated probe from the serum TTV-DNA. *J Gastroenterol Hepatol.* 2001; 16:424–8.

14. Rodriguez-Inigo E, Casqueiro M, Bartolome J, Ortiz-Movilla N, Lopez-Alcorocho JM, Herrero M, et al.

Detection of TT virus DNA in liver biopsies by in situ hybridization. *Am J Pathol.* 2000; 156: 1227–34.

15. Luo K, He H, Zhang L, Liu D, Xiao H, Jiang X, et al. Novel variants related to TT virus distributed widely in China. *J Med Virol.* 2002; 67: 118-26.

16. Charlton M, Adjei P, Poterucha J. TT-virus infection in North American blood donors, patients with fulminant hepatic failure, and cryptogenic cirrhosis. *Hepatology.* 1998; 28: 839-42.

17. Yamamoto T, Kajino K, Ogawa M, Gotoh I, Matsuoka S, Suzuki K, et al. Hepatocellular carcinoma infected with the novel TT DNA virus lack viral integration. *Biochem Biophys Res Commun.* 1998; 251: 339-43.

18. Orii K, Tanaka K, Umemura T. Prevalence and disease association of TT virus infection in Japanese patients with viral hepatitis. *Hepatol Res.* 1999; 14: 161-70.

19. Okamoto H, Nishizawa T, Kato N. Molecular cloning and characterization of a novel DNA virus (TTV) associated with post transfusion hepatitis of unknown etiology. *Hepatol Res.* 1998; 10: 1-16.

20. Hino S, Miyata H. Torque teno virus (TTV): current status. *Rev Med Virol.* 2007; 17:45–57.

21. Takahashi K, Hoshino H, Ohta Y, Yoshida N, Mishiro S. Very high prevalence of TT virus (TTV) infection in general population of Japan revealed by a new set of PCR primers. *Hepatol Res.* 1998; 12, 233–9.

22. Itoh K, Takahashi M, Ukita M, Nishizawa T, Okamoto H. Influence of primers on the detection of TT virus DNA by polymerase chain reaction. *J Infect Dis.* 1999; 180: 1750–1.

23. Bouzari M, Shaykh Baygloo N, Zandieh T. Prevalence of TT virus in general population of Isfahan. *Hakim Research Journal.* 2007; 4: 52-8.

24. Hu YW, Al-Moslih MI, Al Ali MT, Khameneh SR, Perkins H, Diaz-Mitoma F, et al. Molecular detection method for all known genotypes of TT virus (TTV) and TTV-like viruses in thalassemia patients and healthy individuals. *J Clin Microbiol.* 2005; 43: 3747–3754.

25. Hijikata M, Iwata K, Ohta Y, Nakao K, Matsumoto M, Matsumoto H, et al. Genotypes of TT virus (TTV) compared between liver disease patients and healthy individuals using a new PCR system capable of differentiating 1a and 1b types from others. *Arch Virol.* 1999; 144: 2345–54.

26. Viazov S, Ross RS, Varenholz C, Lange R, Holtmann M, Niel C, et al. Lack of evidence for an association between TTV infection and severe liver disease. *J Clin Virol.* 1998; 11:183–7.

27. Niel C, de Oliveira JM, Ross RS, Gomes SA, Roggendorf M, Viazov S. High prevalence of TT virus

infection in Brazilian blood donors. *J Med Virol.*1999; 57:259–63.

28. Irving WL, Ball JK, Berridge S, Curran R, Grabowska AM, Jameson CL, et al. TT virus infection in patients with hepatitis C: frequency, persistence, and sequence heterogeneity. *J Infect Dis.* 1999; 180:27–34.

29. Bouzari M, Mokhtarzadeh A. Frequency of TTV and its role in HBV and HCV infected blood donors in East Azerbaijan province of Iran. *SJIBTO.* 2009; 5: 247-55.

30. Zandie T, Pourfathollah AA, Aminikafiabad S, Samiei Sh, Ranjbar Kermani F, Ghafari K, et al. Measurement TTV prevalence rate by PCR method in plasma of blood donors and recipients in Tehran. *SJIBTO.* 2006; 3: 153-60.

31. Hekmat Doost A, Ghaziani T, Esteghamat FS, Alavian SM, Mohaghegh Shalmani H, Zali MR. TT virus infection in Iranian patients with autoimmune Hepatitis and their controls. *Res Med.* 2006; 28: 163-7.

32. Pourshams A, Azimi K, Kiani L, Sarrafi M, Farhadi Langroodi M. TT Virus Infection Among Iranian Blood Donors: Its Prevalence and Relationship to Serum Alanine Aminotransferase (ALT) Level. *Govaresh.* 2004; 2: 106-9.

33. Jalai Far MA, Zandieh T, Imam SJ, Galehdari H , Pourfathollah AA, Baba Ahmadi M. TTV prevalence in Ahwaz blood donors by using semi-nested PCR. *SJIBTO.* 2007; 3: 389-95.